Biological
NDV-3A
NDV-3A is a biological therapy with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
NCT02996448
completedphase_2
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
NCT03455309
completedphase_1
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
NCT01926028
Clinical Trials (3)
Showing 3 of 3 trials
NCT02996448Phase 2
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
NCT03455309Phase 2
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
NCT01926028Phase 1
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3